gegründet und Immunocore hat erst im Rahmen der Series A zusammen mit NEA, Ridgeback, Orbimed usw. seine 7,55% Anteil an Adaptimmune erworben. Ohne diese Aktion hätte Medigene nun rein gar nichts davon.
Die Geschichte kann man im Prospekt nachlesen
#13850 Seite 44ff
" Our TCR technology was originally developed by Avidex, and was subsequently acquired by Medigene in 2006. We were formed as a new, separate company and licensed our TCR technology for T-cell therapy from Medigene in July 2008. Immunocore was subsequently formed as a new separate company and licensed its TCR technology for soluble TCRs from Medigene later in 2008 to develop soluble TCR proteins. Immunocore currently owns approximately 7.6% of the equity interests in Adaptimmune. "
und Seite 6:
• We have a shared development history with Immunocore Limited, or Immunocore, and share ownership of certain core intellectual property rights with Immunocore. If we fail to maintain our relationship with Immunocore, we could lose important target identification resources that could result in delays in our ability to identify new TCR therapeutic candidates or compromise the sharing of our underlying core intellectual property.
...
• We expect to face intense competition, often from companies with greater resources and experience than we have. In addition, Immunocore also develops affinity-enhanced TCRs. There is a risk that both companies could develop products or therapies that target the same peptide and compete directly with each other.
...
und so ist es auch mit Medigene Seite 122:
"Medigene has also reported development of an engineered TCR therapeutic candidate produced by selection from HLA-mismatched donors rather than affinity-enhancement. We believe that this is still in preclinical stages and is potentially directed at melanoma."
Na also - meine Meinung: lesen!
Zurück
Weiter
